
# D15 — Deployment & Monitoring Design
## Governance Contract

### 1. Lifecycle Identity

- Stage: D15 — Deployment & Monitoring Design
- Source lifecycle stage: D14
- Source Git commit: 1e003ee
- Next lifecycle stage: D16
- Candidate registry ID: DIABETES_READMISSION_XGB_D13_V1
- Candidate model version: 1.0.0
- Candidate system SHA256: 9349A52C715517666540C0D5B1EDB148D48709C0FC2CC77BE9B53F10FE373679
- Frozen operating threshold: 0.12

### 2. D15 Classification

D15 is a pre-deployment architecture, monitoring, operational-governance,
and evidence-design stage for a research/validation clinical decision-support
prototype.

D15 completion does not constitute production deployment authorization.

### 3. Intended Use

The system is designed only to support clinician-reviewed prioritization of
patients for readmission-prevention review.

The model is advisory. It does not autonomously determine discharge,
treatment, care eligibility, or clinical intervention.

### 4. Frozen-System Controls

The following remain frozen during D15:

- D7 preprocessing
- D8 selected development model
- D9 operating threshold
- D13 registered candidate identity
- D14 locked-test results

D15 prohibits silent retraining, refitting, threshold retuning,
recalibration, or locked-test-driven redesign.

### 5. Human Oversight

Human clinical review is required.

Clinical teams retain final decision authority.

AI output must not replace clinician judgment.

### 6. Validation Boundaries

- Internal locked-test validation completed: TRUE
- External validation established: FALSE
- Prospective validation established: FALSE
- Clinical effectiveness established: FALSE
- Production deployment authorized: FALSE

### 7. Residual Risk

All seven D14 residual risks remain unresolved and are carried forward into
D15 monitoring, operational governance, validation-readiness, and escalation
controls.

### 8. Governance Principle

Engineering readiness, monitoring readiness, and governance-design
completion must not be interpreted as evidence of external validity,
clinical effectiveness, or authorization for production clinical use.
